The randomized, double-blind AMEERA-6 trial compared amcenestrant to tamoxifen in patients with hormone receptor-positive, early breast cancer who discontinued adjuvant AI therapy due to toxicity (Table 3) [48,59]. Here, NR4A1 is linked to breast carcinoma.